FORMULATION, DEVELOPMENT AND EVALUATION OF ORODISPERSIBLE TABLET OF GRANISETRON HYDROCHLORIDE
Suresh Kumar Tiwari*, Ruchi Jain, Dr. R.B. Goswami
ABSTRACT
Granisetron hydrochloride is a novel serotonin 5-HT3 receptor used as antiemetic to treat nausea and vomiting during cancer chemotherapy but its oral bioavailability is low due to extensive first pass metabolism in liver which makes it ideal candidates for orodispersible tablet. The present work concerned with the formulation and evaluation of orodispersible tablet of granisetron hydrochloride by using three superdisintegrants like sodium starch glycolate, crospovidone and croscarmellose sodium. Orodispersible tablet of granisetron were prepared by the wet granulation method and blend was evaluated for the pre-compression parameters such as bulk density, compressibility, angle of repose etc. Total nine formulations were prepared and evaluated for hardness, friability, weight variation, content uniformity, wetting time, water absorption ratio, disintegration time and invitro drug release. Pre compression studies revealed good micrometric properties of powder blend. The hardness, friability, drug content and disintegration time of orodispersible tablets were found uniform and reproducible. In-vitro dissolution studies are performed by using phosphate buffer pH 6.8 at 75 rpm by paddle method. Overall, the formulation F7containing of croscarmellose sodium was found to be promising and has shown a disintegration time 45±4sec. The stability studies were performed for two months (accelerated studies) as per ICH guidelines. The optimized formulation (F7) showed no significant variations for the tablets parameters and it was stable for the specified time period. The main aim of the study was to develop orodispersible tablets of granisetron hydrochloride a selective 5- HT3 receptor antagonist (antiemetic agent) for improving patient compliance, especially those of pediatric and geriatric categories with difficulties in swallowing.
[Full Text Article]